{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:59:43Z","timestamp":1761505183637,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.3816\/clc.2010.n.025","type":"journal-article","created":{"date-parts":[[2010,5,3]],"date-time":"2010-05-03T21:29:09Z","timestamp":1272922149000},"page":"192-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Carboplatin\/Pemetrexed\/Bevacizumab in the Treatment of Patients With Advanced Non\u2013Small-Cell Lung Cancer: A Single-Institution Experience"],"prefix":"10.3816","volume":"11","author":[{"given":"Binu","family":"Malhotra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Eaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Stonehouse-Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey J.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLC.2010.n.025_bib1","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CLC.2010.n.025_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.200504-531OE","article-title":"One hundred years of lung cancer","volume":"172","author":"Spiro","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.3816\/CLC.2010.n.025_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/carcin\/bgl253","article-title":"The molecular epidemiology of lung cancer","volume":"28","author":"Schwartz","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.3816\/CLC.2010.n.025_bib4","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.rmed.2006.09.002","article-title":"100 years of lung cancer","volume":"100","author":"Pirozynski","year":"2006","journal-title":"Respir Med"},{"key":"10.3816\/CLC.2010.n.025_bib5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/JTO.0b013e31818020eb","article-title":"The international epidemiology of lung cancer: geographical distribution and secular trends","volume":"3","author":"Youlden","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0140-6736(93)91882-M","article-title":"Polychemotherapy in advanced non small cell lung cancer: a meta-analysis","volume":"342","author":"Souquet","year":"1993","journal-title":"Lancet"},{"key":"10.3816\/CLC.2010.n.025_bib7","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1200\/JCO.1993.11.10.1866","article-title":"Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?","volume":"11","author":"Grilli","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1378\/chest.106.3.861","article-title":"Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a metaanalysis of the literature","volume":"106","author":"Marino","year":"1994","journal-title":"Chest"},{"key":"10.3816\/CLC.2010.n.025_bib9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomized clinical trials","volume":"311","year":"1995","journal-title":"BMJ"},{"key":"10.3816\/CLC.2010.n.025_bib10","series-title":"Progress and Perspectives in Lung Cancer","first-page":"199","article-title":"Best supportive care or chemotherapy for stage IV non small cell lung cancer","author":"Sculier","year":"1999"},{"key":"10.3816\/CLC.2010.n.025_bib11","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0959-8049(97)10122-8","article-title":"Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only: a multicentre randomized phase III trial. Joint Lung Cancer Study Group","volume":"34","author":"Helsing","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLC.2010.n.025_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jnci\/91.1.66","article-title":"Effects of vinorelbine on quality of life and survival of elderly patients with advanced nonsmall-cell lung cancer","volume":"91","author":"The Elderly Lung Cancer Vinorelbine Italian Study Group","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLC.2010.n.025_bib13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2004.09.053","article-title":"American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003","volume":"22","author":"Pfister","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLC.2010.n.025_bib15","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three-platinum based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib16","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non\u2013small-cell lung cancer: a Southwest Oncology Group trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib17","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib18","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm00101a023","article-title":"A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase","volume":"35","author":"Taylor","year":"1992","journal-title":"J Med Chem"},{"key":"10.3816\/CLC.2010.n.025_bib19","first-page":"437","article-title":"Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514","volume":"19","author":"Schultz","year":"1999","journal-title":"Anticancer Res"},{"key":"10.3816\/CLC.2010.n.025_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0065-2571(97)00017-4","article-title":"Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA)","volume":"38","author":"Shih","year":"1998","journal-title":"Adv Enzyme Regul"},{"key":"10.3816\/CLC.2010.n.025_bib21","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/1097-0142(20010801)92:3<595::AID-CNCR1359>3.0.CO;2-D","article-title":"Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group","volume":"92","author":"Shepherd","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CLC.2010.n.025_bib23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/A:1008336931378","article-title":"Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial","volume":"11","author":"Manegold","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1078-0432.690.11.2","article-title":"Pemetrexed combined with oxaliplatin or carboplatin as front-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial","volume":"11","author":"Scagliotti","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLC.2010.n.025_bib25","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/cncr.21480","article-title":"Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer","volume":"104","author":"Zinner","year":"2005","journal-title":"Cancer"},{"issue":"18suppl","key":"10.3816\/CLC.2010.n.025_bib26","first-page":"388s","article-title":"Pemetrexed carboplatin versus gemcitabine carboplatin in the treatment of stage IIIB\/IV nonsmall cell lung cancer","volume":"25","author":"Gr\u00f8nberg","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib27","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib28","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"10.3816\/CLC.2010.n.025_bib29","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel carboplatin alone or with bevacizumab for non-smallcell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"18 suppl","key":"10.3816\/CLC.2010.n.025_bib30","first-page":"388s","article-title":"Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous nonsmall cell lung cancer (NSCLC): BO17704","volume":"25","author":"Manegold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib31","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non\u2013small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib32","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2008.20.8181","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer","volume":"27","author":"Patel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLC.2010.n.025_bib34","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2005.03.045","article-title":"Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published piterature","volume":"23","author":"D\u2019Addario","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.lungcan.2005.11.001","article-title":"Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials","volume":"51","author":"Pujol","year":"2006","journal-title":"Lung Cancer"},{"key":"10.3816\/CLC.2010.n.025_bib36","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.2001.19.6.1734","article-title":"Twenty-two years of phase III trials for patients with advanced non-small cell lung cancer: sobering results","volume":"19","author":"Breathnach","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1513\/pats.200809-110LC","article-title":"Current treatments for advanced stage non-small cell lung cancer","volume":"6","author":"Stinchcombe","year":"2009","journal-title":"Proc Am Thorac Soc"},{"key":"10.3816\/CLC.2010.n.025_bib38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/annonc\/mdl396","volume":"18","author":"Comella","year":"2007","journal-title":"Ann Oncol"},{"key":"10.3816\/CLC.2010.n.025_bib39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.lungcan.2006.01.006","article-title":"Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial","volume":"52","author":"Brodowicz","year":"2006","journal-title":"Lung Cancer"},{"key":"10.3816\/CLC.2010.n.025_bib40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3816\/CLC.2009.n.035","volume":"10","author":"Patel","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.3816\/CLC.2010.n.025_bib41","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1200\/JCO.2009.22.0616","article-title":"Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases","volume":"27","author":"Socinski","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CLC.2010.n.025_bib42","first-page":"452s","article-title":"Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy","volume":"26","author":"Archer","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CLC.2010.n.025_bib44","article-title":"A phase II trial of first-line bevacizumab in combination with pemetrexed and carboplatin in advanced nonsquamous non-small cell lung cancer","volume":"27","author":"Skaff","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730411700183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730411700183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:56:05Z","timestamp":1761504965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730411700183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S1525730411700183"],"URL":"https:\/\/doi.org\/10.3816\/clc.2010.n.025","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carboplatin\/Pemetrexed\/Bevacizumab in the Treatment of Patients With Advanced Non\u2013Small-Cell Lung Cancer: A Single-Institution Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLC.2010.n.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}